Maximising clinical benefit with adequate patient management beyond the second line in mCRC

Guillem Argiles, Dirk Arnold, Gerald Prager, Alberto F. Sobrero, Eric Van Cutsem

Research output: Contribution to journalReview article

Abstract

New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence treatment decision. Available efficacy data suggest treatment with either trifluridine/tipiracil or regorafenib may be appropriate as both can extend patient survival. Thus, the safety profiles of each agent, along with patient performance status, are likely to determine treatment choice. The safety profiles of trifluridine/tipiracil and regorafenib are markedly different: higher levels of non-haematological adverse events such as fatigue, diarrhoea, hypertension and hand-foot skin reaction are reported with regorafenib, while haematological events such as neutropaenia are more common with trifluridine/tipiracil. In general, neutropaenia is a manageable treatment-related toxicity, while hand-foot skin reaction can be troublesome for patients, affecting their ability to carry out everyday activities and get on with their lives, while also affecting treatment adherence. Thus, the occurrence of any potential adverse effects and patient adherence should be closely monitored at each clinic visit. As quality of life is an important issue for patients with mCRC, it is important to balance extended survival and the likely quality of this extended life. Likewise, discussing possible side effects along with treatment expectations with patients can greatly facilitate adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.

Original languageEnglish
Article numbere000495
JournalESMO Open
Volume4
Issue number2
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Colorectal Neoplasms
Trifluridine
Quality of Life
Therapeutics
Foot
Hand
Safety
Skin
Aptitude
Survival
Patient Compliance
Ambulatory Care
Fatigue
Diarrhea
Hypertension
regorafenib

Keywords

  • later-line
  • metastatic colorectal cancer
  • regorafenib
  • treatment
  • trifluridine/tipiracil

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maximising clinical benefit with adequate patient management beyond the second line in mCRC. / Argiles, Guillem; Arnold, Dirk; Prager, Gerald; Sobrero, Alberto F.; Van Cutsem, Eric.

In: ESMO Open, Vol. 4, No. 2, e000495, 01.05.2019.

Research output: Contribution to journalReview article

Argiles, Guillem ; Arnold, Dirk ; Prager, Gerald ; Sobrero, Alberto F. ; Van Cutsem, Eric. / Maximising clinical benefit with adequate patient management beyond the second line in mCRC. In: ESMO Open. 2019 ; Vol. 4, No. 2.
@article{d5a346aac55a4207b61db1d30ab363e5,
title = "Maximising clinical benefit with adequate patient management beyond the second line in mCRC",
abstract = "New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence treatment decision. Available efficacy data suggest treatment with either trifluridine/tipiracil or regorafenib may be appropriate as both can extend patient survival. Thus, the safety profiles of each agent, along with patient performance status, are likely to determine treatment choice. The safety profiles of trifluridine/tipiracil and regorafenib are markedly different: higher levels of non-haematological adverse events such as fatigue, diarrhoea, hypertension and hand-foot skin reaction are reported with regorafenib, while haematological events such as neutropaenia are more common with trifluridine/tipiracil. In general, neutropaenia is a manageable treatment-related toxicity, while hand-foot skin reaction can be troublesome for patients, affecting their ability to carry out everyday activities and get on with their lives, while also affecting treatment adherence. Thus, the occurrence of any potential adverse effects and patient adherence should be closely monitored at each clinic visit. As quality of life is an important issue for patients with mCRC, it is important to balance extended survival and the likely quality of this extended life. Likewise, discussing possible side effects along with treatment expectations with patients can greatly facilitate adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.",
keywords = "later-line, metastatic colorectal cancer, regorafenib, treatment, trifluridine/tipiracil",
author = "Guillem Argiles and Dirk Arnold and Gerald Prager and Sobrero, {Alberto F.} and {Van Cutsem}, Eric",
year = "2019",
month = "5",
day = "1",
doi = "10.1136/esmoopen-2019-000495",
language = "English",
volume = "4",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Maximising clinical benefit with adequate patient management beyond the second line in mCRC

AU - Argiles, Guillem

AU - Arnold, Dirk

AU - Prager, Gerald

AU - Sobrero, Alberto F.

AU - Van Cutsem, Eric

PY - 2019/5/1

Y1 - 2019/5/1

N2 - New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence treatment decision. Available efficacy data suggest treatment with either trifluridine/tipiracil or regorafenib may be appropriate as both can extend patient survival. Thus, the safety profiles of each agent, along with patient performance status, are likely to determine treatment choice. The safety profiles of trifluridine/tipiracil and regorafenib are markedly different: higher levels of non-haematological adverse events such as fatigue, diarrhoea, hypertension and hand-foot skin reaction are reported with regorafenib, while haematological events such as neutropaenia are more common with trifluridine/tipiracil. In general, neutropaenia is a manageable treatment-related toxicity, while hand-foot skin reaction can be troublesome for patients, affecting their ability to carry out everyday activities and get on with their lives, while also affecting treatment adherence. Thus, the occurrence of any potential adverse effects and patient adherence should be closely monitored at each clinic visit. As quality of life is an important issue for patients with mCRC, it is important to balance extended survival and the likely quality of this extended life. Likewise, discussing possible side effects along with treatment expectations with patients can greatly facilitate adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.

AB - New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence treatment decision. Available efficacy data suggest treatment with either trifluridine/tipiracil or regorafenib may be appropriate as both can extend patient survival. Thus, the safety profiles of each agent, along with patient performance status, are likely to determine treatment choice. The safety profiles of trifluridine/tipiracil and regorafenib are markedly different: higher levels of non-haematological adverse events such as fatigue, diarrhoea, hypertension and hand-foot skin reaction are reported with regorafenib, while haematological events such as neutropaenia are more common with trifluridine/tipiracil. In general, neutropaenia is a manageable treatment-related toxicity, while hand-foot skin reaction can be troublesome for patients, affecting their ability to carry out everyday activities and get on with their lives, while also affecting treatment adherence. Thus, the occurrence of any potential adverse effects and patient adherence should be closely monitored at each clinic visit. As quality of life is an important issue for patients with mCRC, it is important to balance extended survival and the likely quality of this extended life. Likewise, discussing possible side effects along with treatment expectations with patients can greatly facilitate adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.

KW - later-line

KW - metastatic colorectal cancer

KW - regorafenib

KW - treatment

KW - trifluridine/tipiracil

UR - http://www.scopus.com/inward/record.url?scp=85065817455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065817455&partnerID=8YFLogxK

U2 - 10.1136/esmoopen-2019-000495

DO - 10.1136/esmoopen-2019-000495

M3 - Review article

VL - 4

JO - ESMO Open

JF - ESMO Open

SN - 2059-7029

IS - 2

M1 - e000495

ER -